MedTrace Logo

Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients

NCT01154842 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2010-07-14

No results posted yet for this study

Summary

Serum FGF-23 levels will be measured in patients with a history of coronary artery disease and aortic valve calcifications.It will be searched whether patients with MPI\>0.47 had higher or lower serum FGF-23 levels than those with MPI\<0.47. Correlations will be examined between log FGF-23 levels and LVMI and MPI. Uni and Multivariable-adjusted regression analyses regarding whether increased log FGF-23 concentrations are independently associated with increased left ventricular mass index and increased MPI, will be performed.

Conditions

  • Fibroblast

Sponsors & Collaborators

  • Diskapi Teaching and Research Hospital

    lead OTHER

Principal Investigators

  • ALPER KIRKPANTUR, Assoc Prof · Diskapi Training and Research Hospital

  • MUSTAFA BALCI, Dr · Diskapi Training and Research Hospital

  • OGUZ GURBUZ, Dr · Diskapi Training and Research Hospital

  • BARIS AFSAR, Dr · Zonguldak Training and Research Hospital

  • BASOL CANBAKAN, Assoc Prof · Diskapi Training and Research Hospital

  • RAMAZAN AKDEMIR, Assoc Prof · Diskapi Training and Research Hospital

  • DENIZ AYLI, Assoc Prof · Diskapi Training and Research Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-05-31
Completion
2010-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154842 on ClinicalTrials.gov